• Santamato A
• Panza F
• Di Venere D
• Solfrizzi V
• Frisardi V
• Ranieri M
• Fiore P

• Botulinum Toxins, Type A
• Bruxism / therapy
• Electromyography
• Neck Pain
• Sleep Wake Disorders

Clinical Features: The patient was a 27-year-old man with nocturnal bruxism and difficulty in active mouth opening and chewing and neck pain at rest. His numeric pain score was 7 of 10. Surface electromyography of the temporalis and masseter muscles showed typical signs of hyperactivity, characterized by compound muscle action potential amplitude alterations.

Intervention and Outcome: After clinical evaluation, he was treated with BTX-A to reduce masseter and temporalis muscle hyperactivity. After 3 days of treatment with BTX-A, with each masseter muscle injected with a dose of about 40 mouse units with a dilution of 1 mL and with temporal muscle bilaterally injected with 25 mouse units with the same dilution, a decrease in bruxism symptoms was reported. Neck pain also decreased after the first treatment (visual analog scale of 2/10) and then resolved completely. After 4 weeks, electromyography showed the reduction of muscle hyperactivity with a decrease in the amplitude of the motor action potential. The same reduction in signs and symptoms was still present at assessment 3 months posttreatment.

Conclusion: These findings suggest that BTX-A may be a therapeutic option for the treatment of bruxism and related disorders.

This abstract is reproduced with the permission of the publisher; full text by subscription.